CJC-1295 (No DAC) + Ipamorelin: Synergy in Research on Growth Hormone Secretion
Introduction
The combination of CJC-1295 (No DAC) and Ipamorelin is among the most studied peptide combinations in the field of endocrinological and metabolic research. Both peptides stimulate the physiological release of growth hormone (GH) through different mechanisms, making researchers interested in their potential synergistic effects.
Unlike exogenous growth hormone, CJC-1295 (No DAC) and Ipamorelin target the pituitary gland's natural regulation. This enables researchers to study the dynamics of pulsatile GH secretion without directly administering growth hormone.
At Peptidera, this combination is offered exclusively for Research Use Only (RUO) and is intended solely for laboratory research.
What is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a synthetic peptide developed as an analogue of Growth Hormone Releasing Hormone (GHRH).
The peptide binds to GHRH receptors in the pituitary gland and thereby stimulates the release of growth hormone according to the natural pulsatile pattern. The No DAC variant has a relatively short duration of action, which is why it is widely used in studies of physiological GH pulses.
Researchers use CJC-1295 (No DAC), among other things, to study:
- regulation of growth hormone secretion;
- endocrine feedback mechanisms;
- metabolic processes;
- aging-related changes.
What is Ipamorelin?
Ipamorelin belongs to the group of Growth Hormone Secretagogues (GHS).
The peptide activates the ghrelin receptor (GHS-R1a), also causing growth hormone release. Compared with older GHRPs, research shows that Ipamorelin produces relatively selective stimulation of growth hormone, with less effect on other pituitary hormones.
Research areas include:
- GH regulation;
- muscle and connective tissue research;
- metabolic regulation;
- repair processes.
Why are both peptides combined?
CJC-1295 (No DAC) and Ipamorelin act via different receptors.
As a result, laboratory research often shows a stronger physiological GH response than when either peptide is used separately.
This synergy makes the combination interesting for studies on:
- growth hormone dynamics;
- body composition;
- protein synthesis;
- regenerative processes;
- age-related changes.
Potential research areas
International research programs have examined, among other things:
- endocrine regulation;
- muscle physiology;
- fat metabolism;
- bone metabolism;
- connective tissue;
- regenerative medicine.
Although preclinical results are promising, additional human research remains necessary to further clarify their clinical significance.
Comparison with other peptides
CJC-1295 (No DAC) versus CJC-1295 DAC
The DAC variant has a considerably longer half-life. The No DAC version is better suited to research into natural growth hormone pulses.
Ipamorelin versus GHRP-2
GHRP-2 generally causes a stronger GH response, but in some studies it also affects other hormones.
Ipamorelin versus GHRP-6
GHRP-6 is known for its potential to stimulate appetite. Ipamorelin is often studied for its relatively selective action on growth hormone.
Recent research developments
Recent publications focus, among other topics, on:
- healthy aging;
- muscle mass during aging;
- metabolic flexibility;
- body composition;
- connective tissue repair;
- endocrine regulation.
In addition, interest is growing in combinations of GH secretagogues with other research peptides.
Frequently asked questions (FAQ)
Is CJC-1295 (No DAC) the same as CJC-1295 DAC?
No. The No DAC variant has a shorter duration of action.
Why do researchers combine CJC-1295 and Ipamorelin?
Because they activate different receptors and can therefore produce a complementary GH response.
Is this combination intended for human use?
No. At Peptidera, these products are available exclusively as Research Use Only.
Which analyses are used?
Depending on the product, methods including HPLC and LC-MS are used.
Is every batch tested?
Yes. Each batch is supplied with a Certificate of Analysis (CoA).
How should the products be stored?
According to the product specifications, refrigerated and protected from light and moisture.
Conclusion
The combination of CJC-1295 (No DAC) and Ipamorelin is among the most studied GH secretagogue combinations in endocrinological research. Thanks to their different mechanisms of action, they form an interesting model for studies on growth hormone regulation, metabolism, and regenerative processes.
At Peptidera, both peptides are offered exclusively for scientific research in accordance with the Research Use Only (RUO) principle.
Meta title
CJC-1295 (No DAC) + Ipamorelin | Research into GH secretion | Peptidera
Meta description
Discover the research on CJC-1295 (No DAC) and Ipamorelin. Learn about mechanisms of action, synergy, recent studies, and Research Use Only at Peptidera.
SEO tags
- CJC-1295 No DAC
- Ipamorelin
- Growth Hormone Secretagogue
- GHRH peptide
- GH research
- Research peptide
- RUO
- Peptidera